Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy

INTRODUCTION: We have suggested that major pathological response (MPR) could serve as a surrogate endpoint for survival and provide rapid means of comparing different neoadjuvant treatment regimens. In here, we confirm that MPR is predictive of long-term overall survival (OS) in patients with NSCLC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Lung Cancer
Main Authors: Weissferdt, Annikka, Pataer, Apar, Vaporciyan, Ara A., Correa, Arlene M., Sepesi, Boris, Moran, Cesar A., Wistuba, Ignacio I., Roth, Jack A., Shewale, Jitesh Baban, Heymach, John V., Kalhor, Neda, Cascone, Tina, Hofstetter, Wayne L., Lee, J. Jack, Swisher, Stephen G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7305995/
https://ncbi.nlm.nih.gov/pubmed/32279936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2019.11.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados